Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
Profitability Metrics
Gross Margin
24.95%
Operating Margin
2.66%
Net Margin
-5.49%
Efficiency Metrics
Revenue per Expense Ratio
1.03
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
20.91%
Income Tax Rate
65,500,000.0%
EPS
-0.9300000000
Balance Sheet Analysis
Current Ratio
0.48
Cash Ratio
0.26
Working Capital
$-362.26M
Debt to Equity
0.96
Debt to Assets
45.33%
Equity Ratio
47.44%
Cash Flow Analysis
Operating Cash Flow Ratio
16.63%
Free Cash Flow Ratio
2.50%
CapEx to Revenue
14.13%
Dividends Paid
$53.58M
Stock Buybacks
$108.54M
Total Shareholder Returns
$162.12M
Cash Position Change
270.47%
Key Takeaways (2023 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 8.96%
Increased R&D investment by 100.00%
Detailed Growth Metrics
Core Performance
Revenue
2.02%
Net Income
8.19%
EPS
-43.08%
Operating Income
-61.96%
Operational Efficiency
R&D Expenses
100.00%
SG&A Expenses
14.30%
Operating Cash Flow
-15.26%
Free Cash Flow
45.80%
Balance Sheet Health
Assets
-5.03%
Debt
-2.48%
Book Value per Share
-1.04%
Inventory
-100.00%
Shareholder Returns
Dividends per Share
8.96%
Shares Outstanding
-6.62%
Long Term Trends
3Y Revenue/Share
243.76%
5Y Revenue/Share
3.27%
3Y Dividend/Share
-33.60%
5Y Dividend/Share
-73.49%